Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC

Inclusion Criteria:

* HCC with diagnosis confirmed pathologically or clinically
* Patients who need to receive TACE and/or HAIC, or have plans to undergo another treatment (3-6 weeks after the previous treatment)
* Child Pugh class A or B
* ECOG PS 0-2
* PLT ≤ 75×10\^9/L (10 days before interventional therapy)

Exclusion Criteria:

* Thrombocytopenia caused by hematological diseases, non chemotherapy related thrombocytopenia (excluding liver cirrhosis with hypersplenism)
* PLT \<30×10\^9/L
* History of hepatic encephalopathy, refractory ascites, or hepatorenal syndrome
* History of arterial or venous thrombosis within 6 months
* Uncontrolled severe infections
* Pregnant or breastfeeding female patients
* Immune deficiencies, such as autoimmune diseases, HIV infected individuals, etc
* Anticoagulation or antiplatelet therapy witch cannot be suspended during the treatment period: heparin, warfarin, rivaroxaban, dipyridamole, non-steroidal anti-inflammatory drugs, aspirin, verapamil, Ticlopidine, clopidogrel, glycoprotein IIb/IIIa antagonists, erythropoietin, etc;
* Administration of blood products within 7 days prior to the baseline visit (excluding albumin infusion)
* Allergy to avatrombopag or any of its formulations
* History (such as gastrointestinal bleeding within 3 months, high risk of thrombosis, such as portal vein main flow velocity\<10cm/s) which may affect the safety of the patients or their ability to complete the study